Highlights
-
The reported prevalence of chronic headaches after aSAH ranges from 16.1% to 41%.
-
Few studies evaluate the long-term impact of chronic headaches in the aftermath of aSAH.
-
Future work in this area may inform the development of clinical guidelines to define the diagnosis and management of chronic headaches after aSAH.
Introduction
The global incidence of aneurysmal subarachnoid hemorrhage (aSAH) is estimated at 6.1 per 100,000 person-years. Reference Etminan, Chang and Hackenberg1 Most survivors develop long-term deficits and dependency, which is well-documented in the literature, with only 30% of patients being discharged home, while the remaining require a combination of assisted living and rehabilitation. Reference Kirkness, Thompson, Ricker, Buzaitis, Newell, Dikmen and Mitchell2 Generally, rebleeding, high-grade aSAH and clinical severity at presentation are associated with worse short-term functional outcomes. Reference Gerner, Reichl and Custal3 While the overall mortality rates associated with aSAH have decreased by approximately 17% in recent decades with the advent of newer endovascular treatment methods, patient-relevant outcomes such as headache, cognitive symptoms and psychological distress among survivors of aSAH are not well characterized. In a survey of 77 survivors of aSAH, headaches were resistant to conventional treatments, with most needing opioids on discharge, suggesting inadequate management of headaches in these patients. Reference Glisic, Gardiner and Josti4 Chronic headaches for 4–7 years after the hospitalization have been reported in the literature, Reference Ogden, Utley and Mee5 but a systematic evaluation of the epidemiology and outcomes of chronic headaches after aSAH has not yet been reported.
To this end, we have performed a systematic review to outline the available literature addressing the disease burden and outcomes of chronic headaches after aSAH.
Methods
Design
This systematic review was reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines Reference Page, McKenzie and Bossuyt6 and registered on PROSPERO (CRD42024509657). Reference Schiavo7
Search strategy
A search of the literature was conducted on December 5, 2023, across five databases (Medline [Ovid], the Cochrane Central Register of Controlled Trials [Ovid], PsychInfo [Ovid], Embase [Ovid] and Scopus [Elsevier]). The references of select and landmark studies were also reviewed to ensure all relevant studies were included. The search was conducted by an information specialist (TK) and developed alongside the lead authors (JBD). This search was repeated on June 18, 2024. The search strategy used a combination of the terms “subarachnoid hemorrhage,” “headache” and “chronic.” Animal-only studies were removed. Only papers published in English were included. No restrictions were placed on age, subarachnoid hemorrhage (SAH) severity or outcome measurement. Case studies and case series were excluded as well. Each strategy was modified accordingly for each database. The full details of the search strategy and specific search terms are included in Supplementary File S2.
Study selection
We included observational studies evaluating the prevalence or associated outcomes of chronic headaches after aSAH. As per International Classification of Headache Disorders guidelines, only studies evaluating headaches 3 months after the ictal event were included. There were no restrictions on the date of publication, recruitment, patient age or baseline clinical characteristics. Review papers, abstracts, conference papers, editorials and case reports were excluded. Given the lack of standardized diagnostic criteria, there were no other restrictions on outcome or assessment measurements.
Interventions
The management of acute and chronic headaches in the aftermath of aSAH is not well-defined. As such, no restrictions were placed on the type of intervention applied toward post-aSAH headaches.
Screening and data abstraction
The studies identified from our database search were uploaded into Covidence, an online platform facilitating collaborative reviews. Reference Goulas8 Two independent authors screened all titles/abstracts and full-texts prior to inclusion/exclusion. All articles with discrepancies at this phase were automatically forwarded to the next screening stage. Discrepancies were resolved by the study lead (JBD) and group consensus.
The details of each study (e.g., author, country, date), baseline clinical features, interventions and outcomes were extracted by two individuals (YJ and NV) – all discrepancies were resolved by a third adjudicator.
Outcomes
The primary outcome was the prevalence of chronic headaches to better understand their disease burden. Secondary outcomes included identifying features associated with persistent headaches and optimal treatment strategies.
Quality assessment
A risk of bias assessment was carried out independently (YJ and NV) using the Newcastle Ottawa Scale (NOS) for cohort studies Reference Lo, Mertz and Loeb9 and the Agency for Healthcare Research and Quality (AHRQ) for cross-sectional studies. Reference Yang, Yang, Yu, Zhan and Sun10 The NOS evaluates the selection, comparability and outcome of each study across eight unique items. Collectively, these items aim to determine if the study population reflects the disease population, if the separate cohorts have similar clinical baseline characteristics and the validity of any chosen outcome measurements. An overall risk of bias is calculated from these independent components. The AHRQ score accounts for selection, performance, attrition, detection and reporting bias, from which a composite risk of bias score is also calculated.
Results
Search results
The initial literature search yielded 1574 studies. The second search in June 2024 resulted in an additional 25 studies, for a total of 1599 results. Of these, 11 were duplicates, resulting in a total of 1588 unique references, as outlined in Figure 1. One additional study was found with a manual search of the sources of the selected full-text studies. In total, there were five studies that met our inclusion criteria.
PRISMA flow diagram.

Characteristics of included studies
The final five studies collectively included 1375 participants. Three studies were retrospective cohort studies, Reference Jaffa, Podell and Smith11–Reference Huckhagel, Klinger, Schmidt, Regelsberger, Westphal and Czorlich13 and the remaining two were cross-sectional, Reference Hong, Joo and Shim14,Reference Yaffe, Green, Butler and Witter15 all published between 2015 and 2021 (Table 1). There were no randomized clinical trials. Outcome timelines were variable across studies, ranging from 52.5 days to 32.6 months. Given the absence of a standardized headache assessment, each study adopted its own clinical criteria to diagnose and monitor chronic headaches after aSAH, ranging from the use of psychometric assessments to a simple visual analog scale. The details of the five studies are summarized in Table 1.
A summary of the studies evaluating chronic headaches after aSAH

aSAH = aneurysmal subarachnoid hemorrhage; EVT = endovascular thrombectomy; mFisher = modified Fisher; VAS = visual analog score; WFNS = World Federation of Neurosurgeons Score.
The overall prevalence of chronic headaches after aSAH ranged from 16.1% to 41%, across a follow-up time frame of 12 months to 7.5 years.
Treatment
Two of the three cohort studies had a pre-existing standardized headache management protocol for patients with aSAH. Reference Jaffa, Podell and Smith11,Reference Gaastra, Carmichael, Galea and Bulters12 Patients in Petridis’s study were treated with a regimen of acetaminophen, metamizole and piritramide, Reference Petridis, Cornelius, Kamp, Falahati, Fischer and Steiger16 while patients in Jaffa et al.’s (2021) study received a mixture of acetaminophen, lidocaine patches, opioids and dexamethasone. Reference Jaffa, Podell and Smith11 None of the cross-sectional studies had a specific headache management protocol.
In one study, endovascular treatment was associated with improved headaches at 1-year follow-up (OR = 2.531; 95% CI 1.141–5.912; P = 0.026), Reference Hong, Joo and Kim17 while in another study, endovascular treatment was associated with slightly higher (and insignificant) headache severity scores at 3 months (VAS 3.4 ± 2.7 vs 8.8 ± 2.0, p < 0.001). Reference Petridis, Kamp and Cornelius18 No other studies found clear associations between clinical or radiographic factors and long-term post-aSAH headaches.
Risk of bias
A risk of bias (ROB) assessment for cohort studies was performed using the NOS. All three studies were found to have a moderate risk of bias, with none addressing the existence/absence of baseline headaches prior to the onset of aSAH (Supplementary Table 1). Furthermore, Jaffa et al. (2021) Reference Jaffa, Podell and Smith11 also did not control for other features, such as age, sex and other comorbidities. Both studies had a moderate risk of bias. Conversely, for the two cross-sectional studies, a ROB analysis was conducted using the AHRQ tool – both studies were found to have a low risk of bias (Supplementary Table 2). A common limitation across the included studies is they do not capture the average sample of the aSAH population; except for Gaastra et al. (2022), Reference Gaastra, Carmichael, Galea and Bulters12 the studies excluded participants with poor clinical presentation at baseline, limiting the conclusions that can be drawn about chronic headaches in poor-grade aSAH. Both studies selectively chose patients with low-grade SAH. Furthermore, neither study performed quality assurance measurements for the primary outcome. While Huckhagel et al. (2020) Reference Huckhagel, Klinger, Schmidt, Regelsberger, Westphal and Czorlich13 did not address confounding variables in their study, Hong et al. (2015) Reference Hong, Joo and Kim17 performed a multiple regression analysis of baseline comorbidities and headache to determine if they had any influence in the development of post-aSAH headaches.
Discussion
Overall, this review illustrates the paucity of literature dedicated toward examining the long-term clinical impact of chronic headaches after aSAH. There are no trials outlining their optimal management or natural history.
Prevalence
Across our five studies, the incidence of chronic headaches after aSAH ranges widely from 16% to 41%. Some chronic headaches associated with aSAH may resolve with time; in one cohort, 50% of patients reported persistent pain at 1-year follow-up, with only 28% reporting persistent pain at the 10-year mark. Reference Gaastra, Carmichael, Galea and Bulters12 Similarly, most patients in another cohort report a decline in the severity of headaches over the course of the first year. Reference Hong, Joo and Shim14 Patients with persistent headaches at 3 years’ time had lower quality of life scores and greater rates of depression, anxiety and opioid use. Reference Huckhagel, Klinger, Schmidt, Regelsberger, Westphal and Czorlich13
However, each study used a unique outcome measurement, with only one study incorporating psychological questionnaires and measurements in their assessments, Reference Huckhagel, Klinger, Schmidt, Regelsberger, Westphal and Czorlich13 suggesting that the full cognitive and social impact of these chronic headaches after aSAH may not be accurately captured by the literature.
Predictive factors
There were no consistent clinical or radiographic factors associated with chronic headaches after aSAH across the studies. In one study, worsening pain over the first week after aSAH, racial/ethnic minority status and a history of depression were associated with greater rates of persistent headaches and opioid dependency over time. Depression has been associated with a greater risk of postoperative opioid use in general. Reference Yaffe, Green, Butler and Witter15 Low socioeconomic status and minority status have been associated with increased rates of inpatient mortality for aSAH, attributed to a greater rate of baseline comorbidities and reduced access to timely care. Reference Jaja, Saposnik and Nisenbaum19 Whether these factors influence the development of chronic headaches after aSAH remains unclear. Most of the studies identified in this review selectively focused on patients with World Federation of Neurosurgeons Score (WFNS) 1 or 2 aSAH and excluded high-grade patients. In one study that included WFNS 3 and 4 patients, headaches were more common in the lower-grade patients. This was explained by the assumption that WFNS 1 and 2 patients were more likely to have insight into the severity of their diagnosis and acute recollections of their hospital stay. Reference Huckhagel, Klinger, Schmidt, Regelsberger, Westphal and Czorlich13 Younger age at presentation was also associated with a greater frequency of chronic headaches; the etiology for this is unclear; however, younger age has been associated with greater headache frequency after SAH and stroke in previous studies. Reference Glisic, Gardiner and Josti4,Reference Harriott, Karakaya and Ayata20
In one study, there was a favorable early effect of open clipping in headache relief; however, this difference was not significant at 3 months – the authors contend this early improvement plays a critical role in accelerated recovery, though there is no long-term data yet to confirm this theory. Reference Petridis, Kamp and Cornelius18 Similarly, another group found that pre-existing migraines tended to resolve more with open clipping over endovascular treatment (77.4% vs 46.7% postoperative pain relief, p = 0.01). Reference Valdueza, Dreier, Woitzik, Dohmen, Sakowitz, Platz, Leistner-Glaess and Witt21 The relationship between the aneurysm treatment modality and long-term headache burden is an area that remains to be further studied, especially as a new era of endovascular treatments unfolds.
One study accounted for pre-existing headaches and found no association with chronic headaches after aSAH, Reference Huckhagel, Klinger, Schmidt, Regelsberger, Westphal and Czorlich13 and the other four studies did not account for this clinical feature.
Treatment
The studies identified in this review were observational in nature – two studies noted center-specific headache management protocols, but these were offered to all included participants with no controls.
A randomized clinical trial outlining the management of chronic headaches after aSAH is not available. As outlined, some institutions have their own internal guidelines for headache management after aSAH, but this remains an understudied area in the literature.
As a result, most patients are treated using opioids as a first-line treatment, particularly for patients with chronic headaches. Persistent headaches are associated with greater rates of opioid use, anxiety and depression, which is a particularly salient issue in light of an ongoing opioid epidemic. Furthermore, long-term opioid use carries a risk of dependency and rebound headaches as well. While there is a growing emphasis on multimodal treatment of headaches, opioids remain the most commonly used agent, and most patients are discharged home with an opioid prescription. Reference Jaffa, Podell and Smith11,Reference Rasouli, Watson, Yaeger, Ladner, Kellner and Dangayach22 As future works aim to identify the factors and etiology of chronic headaches after aSAH, further efforts can be directed toward identifying opioid-sparing treatment strategies.
Limitations and strengths
There are several limitations to our review. The heterogeneity of the selected outcomes precluded any further statistical analysis of the data. Our findings are also generalizable only for patients with low-grade aSAH as most studies excluded patients with high-grade aSAH. This could potentially underestimate the prevalence of post-aSAH chronic headaches as well. This review also was unable to address the influence of baseline demographic features (e.g., medical comorbidities, age, pre-existing headaches) on the prevalence of headaches.
This review outlines the paucity of literature examining the prevalence, etiology and optimal treatment of chronic headaches after aSAH. Across the five studies, we illustrate the inconsistent outcome measurements and diagnostic criteria applied toward chronic headaches after aSAH. We also identify areas for future studies, including the need for a prospective database with consistent follow-up, the need to examine the influence of chronic aSAH on quality of life and a more standardized outcome assessment tool.
Future directions
Chronic headaches are a common sequela of aSAH; however, the diagnostic criteria and treatment paradigms are ill-defined. There are no standardized guidelines to define their diagnosis and management. Conversely, post-traumatic headaches are well-defined in the literature. For example, the Canadian Brain Injury Foundation and Ontario Neurotrauma Foundation have publicly available guidelines for both patients and practitioners to outline headaches and associated symptoms that may occur after head trauma, return to work guidelines and overall treatment guidelines, suggesting a shift away from reliance on oral analgesics. 23,24 Similar guidelines for chronic headaches after aSAH may help standardize the long-term care and management of these patients.
Conclusion
This systematic review outlines the paucity of studies focused on the long-term outcomes of chronic headaches after aSAH. The existing five studies illustrate the variable outcome measurements and follow-up intervals used in this domain, highlighting the need for further standardized and long-term assessment of headaches in survivors.
Supplementary material
The supplementary material for this article can be found at https://doi.org/10.1017/cjn.2025.39.
Acknowledgments
The authors have no additional acknowledgments to declare.
Author contributions
YJ: conceptualization, formal analysis, data curation, writing – original draft, writing – review and editing, visualization. NVdOS: conceptualization, formal analysis, data curation, writing – original draft, writing – review and editing, visualization. TK: formal analysis, data curation. FGA: writing – original draft, writing – review and editing, visualization. EWW: writing – original draft, writing – review and editing, visualization. EPRPA: writing – original draft, writing – review and editing, visualization. TA: writing – original draft, writing – review and editing, visualization. MAK: writing-original draft, writing – review and editing, visualization. KHDI: writing – original draft, writing – review and editing, visualization. MCCS: writing – original draft, writing – review and editing, visualization. ND: writing – original draft, writing – review and editing, visualization. KN: writing – original draft, writing – review and editing, visualization. JL: writing – original draft, writing – review and editing, visualization. PDTL: writing – original draft, writing-review and editing, visualization. JSL: writing – original draft, writing – review and editing, visualization. ATO: writing – original draft, writing – review and editing, visualization, supervision. VP: writing – original draft, writing – review and editing, visualization, supervision. JS: writing – original draft, writing – review and editing, visualization, supervision. TM: writing – original draft, writing – review and editing, visualization, supervision. AZ: writing – original draft, writing – review and editing, visualization, supervision. MVV: writing – original draft, writing – review and editing, visualization, supervision. GS: writing – original draft, writing – review and editing, visualization, supervision. JDD: conceptualization, writing – original draft, writing – review and editing, visualization, supervision.
Funding statement
With respect to this manuscript, the authors do not have any financial support to declare.
Competing interests
TRM serves as the principal of Evasc, MVV holds a New Investigator Award from the Heart and Stroke Foundation of Canada and JDB is a member of the JNIS editorial board.

